Besides, it has been briefly suggested that autophagy modulation by regorafenib could account for its anti-tumor activity [31], but the potential regulatory effects of this multi-kinase inhibitor on FOXO3 and autophagy in sorafenib-resistant HCC has not been investigated yet. Here, FOXO3 is linked to neoplasm.